Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Eman Al Sulais, 1 Turki AlAmeel 2 1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Eman Al SulaisDepartment of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 3191...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al Sulais E, AlAmeel T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	biosimilars inflammatory bowel disease tumor necrosis factor inhibitors Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8b0f7337174e4d028df9e7df5dafc9aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b0f7337174e4d028df9e7df5dafc9aa
record_format	dspace
spelling	oai:doaj.org-article:8b0f7337174e4d028df9e7df5dafc9aa2021-12-02T13:16:36ZBiosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease1177-5491https://doaj.org/article/8b0f7337174e4d028df9e7df5dafc9aa2020-01-01T00:00:00Zhttps://www.dovepress.com/biosimilars-to-antitumor-necrosis-factor-agents-in-inflammatory-bowel--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Eman Al Sulais, 1 Turki AlAmeel 2 1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Eman Al SulaisDepartment of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 31911, Saudi ArabiaEmail e.alslais@gmail.comAbstract: Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients’ concerns.Keywords: biosimilars, inflammatory bowel disease, tumor necrosis factor inhibitorsAl Sulais EAlAmeel TDove Medical Pressarticlebiosimilarsinflammatory bowel diseasetumor necrosis factor inhibitorsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	biosimilars inflammatory bowel disease tumor necrosis factor inhibitors Medicine (General) R5-920
spellingShingle	biosimilars inflammatory bowel disease tumor necrosis factor inhibitors Medicine (General) R5-920 Al Sulais E AlAmeel T Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
description	Eman Al Sulais, 1 Turki AlAmeel 2 1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Eman Al SulaisDepartment of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 31911, Saudi ArabiaEmail e.alslais@gmail.comAbstract: Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients’ concerns.Keywords: biosimilars, inflammatory bowel disease, tumor necrosis factor inhibitors
format	article
author	Al Sulais E AlAmeel T
author_facet	Al Sulais E AlAmeel T
author_sort	Al Sulais E
title	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_short	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_full	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_fullStr	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_full_unstemmed	Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_sort	biosimilars to antitumor necrosis factor agents in inflammatory bowel disease
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8b0f7337174e4d028df9e7df5dafc9aa
work_keys_str_mv	AT alsulaise biosimilarstoantitumornecrosisfactoragentsininflammatoryboweldisease AT alameelt biosimilarstoantitumornecrosisfactoragentsininflammatoryboweldisease
_version_	1718393342975279104

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Ejemplares similares